首页 | 本学科首页   官方微博 | 高级检索  
     

HAPLN1通过IKK/p65信号通路诱导大肠癌HT-29细胞产生MTX耐药
引用本文:贺红柳,崔美英,王丰,冯晔子,袁磊. HAPLN1通过IKK/p65信号通路诱导大肠癌HT-29细胞产生MTX耐药[J]. 中国病理生理杂志, 2019, 35(4): 621-627. DOI: 10.3969/j.issn.1000-4718.2019.04.007
作者姓名:贺红柳  崔美英  王丰  冯晔子  袁磊
作者单位:1. 郑州大学第一附属医院病理科, 河南 郑州 450052;
2. 郑州市第七人民医院心血管内科, 河南 郑州 450000;
3. 漯河医学高等专科学校漯河市医学生物工程重点实验室, 河南 漯河 462002
基金项目:河南省科技厅科技发展计划项目(No.142102310203)
摘    要:目的:研究甲氨蝶呤(methotrexate,MTX)耐药前后人大肠癌(结直肠癌)HT-29细胞中透明质酸蛋白聚糖连结蛋白1(hyaluronan and proteoglycan link protein 1,HAPLN1)表达的变化及其对MTX耐药性的影响,并探究可能的分子机制。方法:采用浓度梯度递增法构建耐药细胞株HT-29/MTX;RT-PCR检测HAPLN1和多药耐药相关蛋白2(multidrug resistance-associated protein 2,MRP2)的mRNA表达水平;采用脂质体介导法将人HAPLN1和MRP2基因的干扰质粒转染HT-29/MTX细胞并筛选出稳定表达的细胞系;采用CCK-8法检测细胞活力;流式细胞术检测细胞凋亡;采用Western blot检测HAPLN1、MRP2、IκB激酶(IκB kinase,IKK)α/β、p-IKKα/β(Ser176/Ser177)、p65和p-p65(Ser536)的蛋白水平。结果:HT-29/MTX细胞中HAPLN1和MRP2的mRNA和蛋白表达水平都显著高于其亲代HT-29细胞(P<0.05),耐药倍数高达463.756。抑制HAPLN1和MRP2基因表达使MTX对HT-29/MTX细胞的IC50从15.304μmol/L分别降至6.119μmol/L和7.801μmol/L,逆转倍数分别为2.501和1.962,并增强MTX诱导的细胞凋亡(P<0.05)。敲减HAPLN1基因表达和使用IKK抑制剂IKK16均可下调IKKα/β和p65蛋白磷酸化水平以及MRP2蛋白表达水平(P<0.05),但IKK16未对HAPLN1蛋白表达产生影响(P>0.05)。结论:敲减HAPLN1基因表达可在体外增强人大肠癌耐药细胞株HT-29/MTX对MTX的敏感性,这可能与其抑制IKK/p65信号通路活化,继而下调MRP2基因表达有关。

关 键 词:结直肠癌  甲氨蝶呤  耐药性  透明质酸蛋白聚糖连结蛋白1  多药耐药相关蛋白2  IKK/p65信号通路
收稿时间:2018-07-09

HAPLN1 induces resistance to MTX in human colorectal cancer HT-29 cells though IKK/p65 pathway
HE Hong-liu,CUI Mei-ying,WANG Feng,FENG Ye-zi,YUAN Lei. HAPLN1 induces resistance to MTX in human colorectal cancer HT-29 cells though IKK/p65 pathway[J]. Chinese Journal of Pathophysiology, 2019, 35(4): 621-627. DOI: 10.3969/j.issn.1000-4718.2019.04.007
Authors:HE Hong-liu  CUI Mei-ying  WANG Feng  FENG Ye-zi  YUAN Lei
Affiliation:1. Department of Pathology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China;
2. Department of Cardiovasology, Zhengzhou Seventh People's Hospital, Zhengzhou 450000, China;
3. Key Laboratory of Medical Bioenginee-ring of Luohe City, Luohe Medical College, Luohe 462002, China
Abstract:AIM:To investigate the changes of hyaluronan and proteoglycan link protein 1 (HAPLN1) expression before and after resistance to methotrexate (MTX) in human colorectal cancer HT-29 cells and its effect on this drug resistance, and to explore the molecular mechanism in the process. METHODS:The drug-resistant HT-29/MTX cells were established by stepwise exposure of the cells to MTX, and then the HT-29/MTX cells were stably transfected with specific shRNA interference plasmid vectors targeting HAPLN1 and multidrug resistance-associated protein 2 (MRP2). The mRNA expression levels of HAPLN1 and MRP2 were measured by RT-PCR. CCK-8 assay was used to detect the viability of HT-29/MTX cells. The apoptosis rate was analyzed by flow cytometry. The protein levels of HAPLN1, MRP2, IκB kinase (IKK) α/β, p-IKKα/β (Ser176/Ser177), p65 and p-p65 (Ser536) were determined by Western blot. RESULTS:The HT-29/MTX cells had significantly higher mRNA and protein levels of HAPLN1 and MRP2 than HT-29 cells (P<0.05) with resistant factor of 463.756. HAPLN1 and MRP2 gene silencing significantly increased the cytotoxicity and apoptosis of HT-29/MTX cells induced by MTX (P<0.05). The IC50 value was decreased from 15.304 μmol/L to 6.119 μmol/L and 7.801 μmol/L, respectively, and their reversal folds were 2.501 and 1.962, respectively. Silencing of HAPLN1 and IKK inhibitor IKK16 inhibited the phosphorylation of IKKα/β and p65 (P<0.05), and down-regulated the protein level of MRP2 in the HT-29/MTX cells (P<0.05). However, IKK16 did not affect the protein level of HAPLN1 in the HT-29/MTX cells.CONCLUSION:Knock-down of HAPLN1 gene expression reverses the resistance to MTX in human colorectal cancer HT-29/MTX cells possibly by blocking the IKK/p65 signaling pathway and thus down-regulating the expression of MRP2.
Keywords:Colorectal cancer  Methotrexate  Drug resistance  Hyaluronan and proteoglycan link protein 1  Multidrug resistance-associated protein 2  IKK/p65 signaling pathway
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《中国病理生理杂志》浏览原始摘要信息
点击此处可从《中国病理生理杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号